The Medical Letter on Drugs and Therapeutics
Benralizumab (Fasenra) for Severe Eosinophilic Asthma
The full article is available to subscribers Subscriber Login   

The FDA has approved benralizumab (Fasenra – AstraZeneca), a humanized monoclonal antibody selective for the interleukin-5 (IL-5) receptor, for add-on maintenance treatment of severe asthma in patients ≥12 years old with an eosinophilic phenotype. Benralizumab is the third anti-IL-5 antibody to be approved for treatment of severe eosinophilic asthma; mepolizumab (Nucala) and reslizumab (Cinqair), which target IL-5 itself, were approved earlier.1,2

MECHANISM OF ACTION — Severe asthma often has an eosinophilic phenotype with elevated blood and lung eosinophil levels.3,4 IL-5 is the major cytokine responsible for the growth, differentiation, recruitment, activation, and survival of eosinophils. Mepolizumab and reslizumab, the two previously approved anti-IL-5 antibodies, reduce the production and survival ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Benralizumab (Fasenra) for Severe Eosinophilic Asthma
Article code: 1541a
 Electronic, downloadable article - $25